Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 5/20 | 1.00 |
| ▸ | METAP2 | P50579 | 2/20 | 1.00 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 1.00 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.70 |
| ▸ | MAPT | P10636 | 4/20 | 0.59 |
| ▸ | ROCK2 | O75116 | 4/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.59 |
| ▸ | MEN1 | O00255 | 3/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.59 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.59 |
| ▸ | GAA | P10253 | 1/20 | 0.59 |
| ▸ | HPGD | P15428 | 1/20 | 0.59 |
| ▸ | RAB9A | P51151 | 1/20 | 0.59 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.59 |
| ▸ | CLK1 | P49759 | 2/20 | 0.53 |
| ▸ | GSK3B | P49841 | 2/20 | 0.53 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.53 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cyanate SCHEMBL27871749 | 0.89 | NOS1 (0.79) | NOS1METAP2CSNK2A1DYRK1AMAPT | |
| SCHEMBL5902 | 0.83 | NOS1 (1.00) | NOS1METAP2CSNK2A1DYRK1AMAPT | |
| SCHEMBL29364542 | 0.83 | NOS1 (1.00) | NOS1METAP2CSNK2A1DYRK1AMAPT | |
| Tert-Butyl Formate SCHEMBL27690305 | 0.81 | NOS1 (0.66) | NOS1METAP2CSNK2A1DYRK1AMAPT | |
| SCHEMBL27731429 | 0.79 | NOS1 (0.62) | NOS1METAP2CSNK2A1DYRK1AMAPT | |
| SCHEMBL27708259 | 0.78 | CSNK2A1 (0.60) | NOS1METAP2CSNK2A1DYRK1AMAPT | |
| Hydrazine SCHEMBL16698268 | 0.78 | NOS1 (0.89) | NOS1METAP2CSNK2A1DYRK1AMAPT | |
| SCHEMBL13122080 | 0.74 | ROCK2 (0.67) | NOS1METAP2CSNK2A1DYRK1AROCK2 | |
| SCHEMBL277777 | 0.74 | ROCK2 (0.59) | NOS1METAP2CSNK2A1DYRK1AMAPT | |
| SCHEMBL264176 | 0.74 | NOS1 (1.00) | NOS1METAP2CSNK2A1DYRK1AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1768 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260109670-A1 | METHOD FOR ARYL DEBROMINATION AND ACYLATION OF BROMINATED BENZO-FUSED NITROGEN HETEROCYCLE | Shanghai OuChem Bio-Technology Co., LTD (CN) | 2026-04-23 | — | — | US | claimed |
| CN-119751424-A | Novel method for synthesizing Bei Shude mol of methanesulfonic acid | 重庆圣华曦药业股份有限公司 | 2025-04-04 | — | — | CN | claimed |
| WO-2023122498-A1 | ONE-STEP OXIDE BATH FOR IMPROVING ADHESION OF POLYMERIC MATERIALS TO METAL SUBSTRATES | MACDERMID, INCORPORATED (US) | 2023-06-29 | — | — | WO | claimed |
| US-20230199972-A1 | One-Step Oxide Bath for Improving Adhesion of Polymeric Materials to Metal Substrates | MACDERMID, INCORPORATED | 2023-06-22 | — | — | US | claimed |
| CN-114287437-A | Atrazine topramezone dispersible suspending agent and preparation method and application thereof | 山东德浩化学有限公司 | 2022-04-08 | — | — | CN | claimed |
| CN-111995577-A | Synthetic method of 4-fluoro indazole 3-carbonitrile or derivatives thereof | 上海代为化学科技有限公司 | 2020-11-27 | — | — | CN | claimed |
| US-20260146035-A1 | FUSED BICYCLIC COMPOUNDS AND THEIR USE AS MER AND AXL INHIBITORS | DONG-A ST CO., LTD. (KR) | 2026-05-28 | — | — | US | disclosed |
| CN-122010905-A | Pyrazolyl derivatives as anticancer agents | 诺华股份有限公司 | 2026-05-12 | — | — | CN | disclosed |
| US-20260125367-A1 | CANCER TREATMENTS TARGETING CANCER STEM CELLS | REMEDY PLAN, INC. (US) | 2026-05-07 | — | — | US | disclosed |
| US-20260124197-A1 | NOVEL HETEROBICYCLIC COMPOUND FOR INHIBITING YAP-TEAD INTERACTION AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | HANMI PHARMACEUTICAL CO LTD (KR) | 2026-05-07 | — | — | US | disclosed |
| US-12612412-B2 | Antiviral heterocyclic compounds | ENANTA PHARMACEUTICALS, INC. (US) | 2026-04-28 | — | — | US | disclosed |
| US-20260109670-A1 | METHOD FOR ARYL DEBROMINATION AND ACYLATION OF BROMINATED BENZO-FUSED NITROGEN HETEROCYCLE | Shanghai OuChem Bio-Technology Co., LTD (CN) | 2026-04-23 | — | — | US | disclosed |
| EP-3886904-B1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2026-04-22 | — | — | EP | disclosed |
| WO-1997049698-A1 | PIPERIDINE ACETIC ACID DERIVATIVES AND THEIR USE IN THE TREATMENT OF THROMBOTIC DISORDERS | GLAXO GROUP LIMITED (GB) | 1997-12-31 | — | — | WO | disclosed |
| WO-1996041803-A1 | PIPERIDINEACETIC ACID DERIVATIVES AS INHIBITORS OF FIBRINOGEN-DEPENDENT BLOOD PLATELET AGGREGATION | GLAXO GROUP LIMITED (GB) | 1996-12-27 | — | — | WO | disclosed |
| EP-0137223-B1 | PHOTOGRAPHIC IMAGE-RECEIVING ELEMENT FOR SILVER SALT DIFFUSION TRANSFER PROCESS | FUJI PHOTO FILM CO., LTD. (JP) | 1988-05-11 | — | — | EP | disclosed |
| US-4585725-A | STORAGE STABILITY | FUJI PHOTO FILM CO., LTD. (JP) | 1986-04-29 | — | — | US | disclosed |
| EP-0137223-A2 | Photographic image-receiving element for silver salt diffusion transfer process | FUJI PHOTO FILM CO., LTD. (JP) | 1985-04-17 | — | — | EP | disclosed |
| US-3963495-A | Image-receiving element for silver salt diffusion transfer with layer of monoacrylates or monomethacrylates of polyhydric alcohols | FUJI PHOTO FILM CO., LTD. (JA) | 1976-06-15 | — | — | US | disclosed |
| US-3931220-A | FUNGICIDE, BACTERICIDE | BAYER AKTIENGESELLSCHAFT (DT) | 1976-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260124197-A1 | NOVEL HETEROBICYCLIC COMPOUND FOR INHIBITING YAP-TEAD INTERACTION AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | YAP1, RCC1, YES1 | NOS1 2861/4885METAP2 4684/4885CSNK2A1 40/4885 |
| US-20260109670-A1 | METHOD FOR ARYL DEBROMINATION AND ACYLATION OF BROMINATED BENZO-FUSED NITROGEN HETEROCYCLE | NAT1, AADAC, NAA15 | NOS1 496/4885METAP2 3620/4885CSNK2A1 930/4885 |
| US-20260146035-A1 | FUSED BICYCLIC COMPOUNDS AND THEIR USE AS MER AND AXL INHIBITORS | AXL, ERBB2, ERBB3 | NOS1 1796/4885METAP2 2307/4885CSNK2A1 272/4885 |
| US-12612412-B2 | Antiviral heterocyclic compounds | ZC3HAV1, NHERF1, HM13 | NOS1 2373/4885METAP2 371/4885CSNK2A1 2167/4885 |
| US-20260125367-A1 | CANCER TREATMENTS TARGETING CANCER STEM CELLS | MCL1, MALT1, BCL6 | NOS1 2646/4885METAP2 3697/4885CSNK2A1 1660/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.